| Literature DB >> 22747701 |
Samuel P Sussmilch-Leitch1, Natalie J Collins1,2, Andrea E Bialocerkowski3, Stuart J Warden4, Kay M Crossley1,2,5.
Abstract
BACKGROUND: Achilles tendinopathy (AT) is a common condition, causing considerable morbidity in athletes and non-athletes alike. Conservative or physical therapies are accepted as first-line management of AT; however, despite a growing volume of research, there remains a lack of high quality studies evaluating their efficacy. Previous systematic reviews provide preliminary evidence for non-surgical interventions for AT, but lack key quality components as outlined in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement. The aim of this study was to conduct a systematic review and meta-analysis (where possible) of the evidence for physical therapies for AT management.Entities:
Year: 2012 PMID: 22747701 PMCID: PMC3537637 DOI: 10.1186/1757-1146-5-15
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 2.303
Figure 1Flow chart of the process and rationale used in selecting studies for inclusion.
Quality ratings and inter-rater reliability using the Modified PEDro Scale of reviewed studies (N = 23)
| | |||||||||||||||
| Costa 2005 | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | |
| Tumilty 2008 | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | | |
| Rasmussen 2008 | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | | | |
| Rompe 2007 | ✓ | ✓ | ✓ | ✓ | | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | |
| Rompe 2008 | ✓ | ✓ | ✓ | ✓ | | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | |
| Rompe 2009 | ✓ | ✓ | ✓ | ✓ | | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | |
| Silbernagel 2007 | ✓ | ✓ | ✓ | ✓ | | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | | | |
| Stergioulas 2008 | ✓ | ✓ | | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | | ✓ | |
| de Jonge 2010 | ✓ | ✓ | ✓ | ✓ | | | ✓ | ✓ | ✓ | ✓ | | ✓ | | | |
| Chapman-Jones 2002 | ✓ | ✓ | ✓ | ✓ | | | | ✓ | | ✓ | ✓ | ✓ | | | |
| Herrington 2007 | ✓ | ✓ | ✓ | ✓ | | | ✓ | ✓ | | ✓ | | | | ✓ | |
| Mafi 2001 | ✓ | ✓ | ✓ | | | | | | ✓ | ✓ | ✓ | ✓ | | ✓ | |
| Chester 2008 | ✓ | ✓ | ✓ | | | | ✓ | | | ✓ | ✓ | | | ✓ | |
| ✓ | ✓ | | | | | | | | |||||||
| Knobloch 2007 | | ✓ | | ✓ | | | ✓ | ✓ | ✓ | ✓ | | | ✓ | | |
| Knobloch 2008 | ✓ | ✓ | | | | | ✓ | ✓ | | ✓ | ✓ | | | | |
| McAleenan 2010 | ✓ | ✓ | ✓ | | | | | | | ✓ | | | ✓ | ✓ | |
| Petersen 2007 | ✓ | ✓ | | ✓ | | | | ✓ | | ✓ | ✓ | | | | |
| Silbernagel 2001 | ✓ | ✓ | | | | | ✓ | ✓ | | ✓ | ✓ | | | | |
| ✓ | ✓ | | | | | | | | | | | ||||
| Niesen-Vertommen 1992 | | ✓ | | ✓ | | | | ✓ | | ✓ | | | | | |
| ✓ | ✓ | | | | | | | | | | | ||||
| ✓ | ✓ | | | | | | | | | | | | | ||
Listing in descending order of quality rating.
Ticks indicate where a point was awarded for the criterion. Studies highlighted with bold and italic font were rated as having a high risk of bias.
Participant characteristics
| Silbernagel 2001 | M | C | A: 22 | A: 5 (23) | A: 47 (15) | A: 9, 7, 4–96 |
| | | | B: 18 | B: 4 (22) | B: 41 (10) | B: 18,13, 6-192 |
| Chester 2008 | M | C | A: 8 | A: 4 (50) | A: 59 (10) | A: 23,13, NR |
| | | | B: 8 | B: 1 (13) | B: 48 (12) | B: 14,10, NR |
| Mafi 2001 | M | C & US | A: 22 | A: 10 (45) | A:48 (10) | A: 18, NR, 3–120 |
| | | | B: 22 | B: 10 (45) | B: 48 (8) | B: 23, NR, 5-120 |
| Rompe 2007 | M | C & US | A: 25 | A: 16 (64) | A: 48 (10) | A: 11, 8, NR |
| | | | B: 25 | B: 16 (64) | B: 46 (11) | B: 9, 11, NR |
| Herrington 2007 | M | C | A: 13 | NR | A: 37 (9) | A: 21,18, NR |
| | | | B: 12 | B: 37 (7) | B: 28,13, NR | |
| Knobloch 2007 | All | C | A: 15 | A: 7 (47) | A: 33 (12) | A: NR |
| | | | B: 5 | B: 2 (40) | B: 32 (10) | B: NR |
| Niesen-Vertommen 1992 | NR | NR | A: 8 | A: 4 (50) | A: 35 (NR) | A: 4, NR, NR |
| | | | B: 9 | B: 3 (33) | B: 34 (NR) | B: 4, NR, NR |
| Petersen 2007 | M | C & US | A: 37 | A: 14 (38) | A: 42 (11) | A: 7, 3, NR |
| | | | B: 35 | B: 15 (43) | B: 42 (11) | B: 7, 3, NR |
| Rasmussen 2008 | NR | C | A: 24 | A: 12 (50) | A: 49 (9) | A: NR |
| | | | B: 24 | B: 16 (67) | B: 46 (13) | B: NR |
| Costa 2005 | All | C | A: 22 | A: 13 (59) | A: 58 (11) | A: 18,10, NR |
| | | | B: 27 | B: 15 (56) | B: 47 (13) | B: 21, 21, NR |
| Rompe 2007 | M | C & US | A: 25 | A: 14 (56) | A: 51 (10) | A: 13, 7, NR |
| | | | B: 25 | B: 16 (64) | B: 46 (11) | B: 9, 11, NR |
| | | | C: 25 | C: 16 (64) | C: 48 (10) | C: 11, 8, NR |
| Rompe 2008 | I | C & US | A: 25 | A: 16 (64) | A: 40 (11) | A: 26,11, NR |
| | | | B: 25 | B: 14 (56) | B: 39 (11) | B: 25, 8, NR |
| Rompe 2009 | M | C & US | A: 34 | A: 18 (53) | A: 53 (10) | A: 16, 5, NR |
| | | | B: 34 | B: 20 (59) | B: 46 (10) | B: 13, 7, NR |
| de Jonge 2010 | M | C | A: 36 | A: 14 (39) | A: 45 (9) | A: 28, 46, NR |
| | | | B: 34 | B: 12 (35) | B: 44 (7) | B: 34, 56, NR |
| McAleean 2010 | NR | C | A: 5 | A: 2 (40) | A: 42 (6) | A 11, 14, NR |
| | | | B: 6 | B: 3 (50) | B: 40 (9) | B: 19, 12, NR |
| Knobloch 2008 | M | C | A: 43 | A: 14 (33) | A: 47 (11) | A: NR |
| | | | B: 54 | B: 20 (37) | B: 48 (11) | B: NR |
| Petersen 2007 | M | C & US | A: 28 | A: 11 (39) | A: 43 (12) | A: 7, 2, NR |
| | | | B: 37 | B: 14 (38) | B: 42 (11) | B: 7, 3, NR |
| Stergioulas 2008 | M | C | A: 20 | A: 8 (40) | A: 30 (5) | A: 10, 3, NR |
| | | | B: 20 | B: 7 (35) | B: 29 (5) | B: 9, 3, NR |
| Tumilty 2008 | M | NR | A: 10 | A: 3 (33) | A: 41 (7.6) | A: 4, NR, NR |
| | | | B: 10 | B: 6 (60) | B: 43 (8.5) | B: 4, NR, NR |
| Chapman-Jones 2002 | NR | C | A: 24 | A: 6 (25) | A: 39 (10.4) | A: NR |
| | | | B: 24 | B: 7 (29) | B: 36 (7.8) | B: NR |
| Silbernagel 2007 | M | C | A: 26 | A: 7 (37) | A: 44 (8.8) | A: 48, 85, 3–360 |
| B: 25 | B: 11 (58) | B: 48 (6.8) | B: 24, 41, 3-168 | |||
All = includes both I & M; C = clinical; I = insertional; M = midportion; NA = not applicable; NR = not reported; US = ultrasound.
Figure 2Standardised mean differences for outcomes of pain ± function following intervention with exercise modalities. EE = eccentric exercise; SWT = shock wave therapy. * denotes use of conservative therapy in addition to presented modality.
Physical therapies for Achilles tendinopathy
| Mafi 2001 | A: Eccentric exercise | A: 22 | 12 | A vs B | 12wk: ID | Between groups comparisons of pain not presented; Significant within-group improvement in pain VAS for both eccentric and concentric exercise in those who were satisfied with treatment ( |
| | B: Concentric exercise | B: 22 | | VASa | | |
| Niesen-Vertommen 1992 | A: Eccentric exercise | A: 8 | 12 | A vs B | 4wk: ID | Eccentric exercise had a greater reduction of pain (p < 0.01) |
| | B: Concentric exercise | B: 9 | | VASo | 8wk: ID | |
| | | | | | 12wk: ID | |
| Rompe 2007 | A: Eccentric exercise | A: 25 | 12 | A vs B | 16wk:–1.26 (–1.87:–0.65) | |
| | B: Wait and see approach | B: 25 | | VISA-A | | |
| Knobloch 2007 | A: Eccentric exercise | A: 15 | 12 | A vs B | 12wk: -1.67 (−2.83: -0.50) | |
| | B: Cryotherapy | B: 5 | | VASo | | |
| Petersen 2007 | A: Eccentric exercise | A: 37 | 12 | A vs B | 6wk: ID | No difference between groups (p < 0.05) |
| | B: Heel brace | B: 35 | | VASa | 12wk: ID | |
| | | | | | 54wk: ID | |
| Rompe 2008 | A: Shock wave therapy | A: 25 | A: 3 | B vs A | 16wk: -1.40 (−0.74: -2.06) | |
| | B: Eccentric exercise | B: 25 | B: 12 | VISA-A | | |
| Chester 2008 | A: Eccentric exercise | A: 8 | A: 12 | A vs B | 6wk: 0.63 (−0.33: 1.58) | |
| | B: Ultrasound | B: 8 | B: ≤6 | VASs | 12wk: 0.24 (−0.69: 1.17) | |
| Silbernagel 2001 | A: Rehabilitation programme including single leg eccentric loading | A: 22 | 12 | A vs B | 6wk: ID | Eccentric loading had better strength and pain outcomes (p < 0.05) |
| | | B: 18 | | VASj | 12wk: ID | |
| | B: Rehabilitation programme | | | | 26wk: ID | |
| | | | | | 52wk: ID | |
| Herrington 2007 | A: Eccentric exercise + deep friction massage + ultrasound + calf stretches | A: 13 | 12 | A vs B | 4wk: ID | Eccentric exercise produced superior pain and function outcomes (p = 0.01) |
| | B: Deep friction massage + ultrasound + calf stretches | B: 12 | | VISA-A | 8wk: ID | |
| | | | | | 12wk: ID | |
| Costa 2005 | A: Shock wave therapy | A: 22 | 12 | A vs B | 12wk: -0.44 (−1.01: 0.13) | |
| | B: Sham shock wave therapy | B: 27 | | VASw | 52 wk: ID | |
| Rompe 2007 | A: Shock wave therapy | A: 25 | A: 3 | A vs B | 16wk: -1.03 (−1.62:-0.44) | |
| | B: Wait and see approach | B: 25 | B: 12 | VISA-A | | |
| | C: Eccentric exercise | C: 25 | C: 12 | A vs C | 16 wk: 0.29 (−0.27: 0.85) | |
| | | | | VISA-A | | |
| Rompe 2008 | A: Shock wave therapy | A: 25 | A: 3 | A vs B | 16wk: -1.40 (−2.03: -0.78) | |
| | B: Eccentric exercise | B: 25 | B: 12 | VISA-A | | |
| Rompe 2009 | A: Shock wave therapy + eccentric exercise | A: 34 | A: 12 | A vs B | 16wk: -0.76 (−1.28: -0.24) | |
| | B: Eccentric exercise | B: 34 | B: 12 | VISA-A | | |
| Rasmussen 2008 | A: Shock wave therapy + conservative therapy | A: 24 | 4 | A vs B | 4wk: -0.52 (−1.10: 0.06) | |
| | B: Sham shock wave therapy + conservative therapy | B: 24 | | AOFAS | 8wk: ID | |
| | | | | | 12wk: ID | |
| Stergioulas 2008 | A: Laser therapy + eccentric exercise | A: 20 | 8 | A vs B | 4wk: -1.07 (−1.65: -0.49) | |
| | B: Placebo laser therapy + eccentric exercise | B: 20 | | VASa | 8wk: -1.14 (−1.82: -0.47) | |
| | | | | | 12wk: -0.78 (−1.42: -0.13) | |
| Tumilty 2008 | A: Laser therapy + eccentric exercise | A: 10 | 12 | A vs B | 4wk: 0.53 (−0.36: 1.43) | |
| | B: Placebo laser therapy + eccentric exercise | B: 10 | | VASm | 12wk: -0.25 (−1.13: 0.64) | |
| Chapman-Jones 2002 | A: Microcurrent therapy + eccentric exercise | A: 24 | 12 | A vs B | 12wk: ID | Microcurrent therapy produced superior pain, stiffness and function outcomes (p < 0.001) |
| | B: Eccentric exercise11 | B: 24 | | VASa | 26wk: ID | |
| | | | | | 52wk: ID | |
| Silbernagel 2007 | A: Rehabilitation programme + continued tendon loading activity | A: 26 | 12- 26 | A vs B | 6wk: -0.32 (−0.88: 0.25) | |
| | B: Rehabilitation programme + no tendon loading activity (running or jumping) | B: 25 | | VISA-A-S | 12wk: -0.17 (−0.73: 0.39) | |
| | | | | | 26wk: -0.12 (−0.68: 0.44) | |
| | | | | | 52wk: -0.55 (−1.11: 0.02) | |
| de Jonge 2010 | A: Night splint + eccentric exercise | A: 36 | 12 | A vs B | 4wk: -0.12 (−0.61: 0.37) | |
| | B: Eccentric exercise | B: 34 | | VISA-A | 12wk: 0.07 (−0.43: 0.56) | |
| | | | | | 52wk: -0.10 (−0.60: 0.40) | |
| McAleenan 2010 | A: Night splint + eccentric exercise | A: 5 | 12 | A vs B | 12wk: -1.09 (−2.41: 0.22) | |
| | B: Eccentric exercise | B: 6 | | VISA-A | | |
| Knobloch 2008 | A: Heel brace + eccentric exercise | A: 43 | 12 | A vs B | 12wk: -0.29 (−0.70: 0.12) | |
| | B: Eccentric exercise | B: 54 | | VASo | | |
| Petersen 2007 | A: Heel brace + eccentric exercise | A: 28 | 12 | A vs B | 6wk: ID | No difference between groups (p < 0.05) |
| | B: Eccentric exercise | B: 37 | | VASw | 12wk: ID | |
| 54wk: ID | ||||||
CI = confidence interval; ID = insufficient data; NR = not reported; PES = Pain Experience Index; SD = standard deviation; SMD = standard mean difference; wk = week; VAS = visual analogue scale; VISA-A = Victorian Institute of Sports Assessment – Achilles; VISA-A-S Victorian Institute of Sports Assessment – Achilles Swedish; VASa = pain during activity; VASj = pain during jumping; VASm = pain in the morning; VASo = pain overall; VASs = pain after sport & recreation; VASw = pain during walking.
Figure 3Standardised mean differences for outcomes of pain ± function following electrophysical therapies. SWT = shock wave therapy; EE = eccentric exercise. * denotes use of rehabilitation program in addition to presented modality.
Figure 4Standardised mean differences for outcomes of pain with braces and splints. EE = eccentric exercise